China’s NMPA Approves Shenzhen Chipscreen’s Chidamide for DLBCL Indication
Shenzhen Chipscreen Biosciences Co., Ltd, a biopharmaceutical company based in China, announced that it has...
Fineline Cube
Siemens Healthineers AG Partners with Haidian District Government to Boost Medical Innovation in Beijing
Siemens Healthineers AG (ETR: SHL), a leading medical technology company based in Germany, has entered...
Hainan Poly Pharm’s Manufacturing Units Get GMP Nod From Saudi Food and Drug Authority
Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, announced that it has...
GBA Center of NMPA Launches Filing Guidance for Pharmaceutical Enterprises
The Guangdong-Hong Kong-Macau Greater Bay Area (GBA) Center for Drug Evaluation and Inspection, under the...
Keymed Biosciences’ IL-4Rα Monoclonal Antibody for Allergic Rhinitis Accepted by China NMPA
China-based biopharmaceutical company Keymed Biosciences Inc. (HKG: 2162) has announced that the National Medical Products...
Bristol-Myers Squibb’s Camzyos Approved by China’s NMPA for Hypertrophic Cardiomyopathy Treatment
Bristol-Myers Squibb (BMS; NYSE: BMY) has received marketing approval from China’s National Medical Products Administration...
Cutia Therapeutics Submits New Drug Application for Androgenic Alopecia Treatment in Hong Kong
Cutia Therapeutics (HKG: 2487), a dermatology-focused pharmaceutical company, has announced the submission of a New...
Zhejiang Huahai Pharmaceutical Wins IND Approval for Antibody-Drug Conjugate from China’s NMPA
Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a China-based pharmaceutical company, has announced that it...
German Study Highlights Potential of Amgen’s Blinatumomab in Treating Rheumatoid Arthritis
Researchers from Germany’s University of Erlangen-Nuremberg have unveiled promising clinical data on the use of...
U.S. Judge Dismisses Johnson & Johnson and Bristol-Myers Squibb Lawsuits Against Drug-Pricing Provisions in Inflation Reduction Act
In a recent legal development, a U.S. federal court judge has rejected the legal challenges...
Sino Biological Inc. to Acquire Canadian Bioactive Enzyme Manufacturer SignalChem Biotech
Sino Biological Inc. (SHE: 301047), a leading provider of biological research reagents and technical contract...
China’s Q1 2024 Pharma Trade Registers 6.3% Growth Amid Global Recovery
The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...
Dizal Pharmaceutical’s Sunvozertinib Logs RMB 91.29 Million in Sales Following EGFR Inhibitor Approval
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a spin-off from AstraZeneca China, has announced that its...
WuXi AppTec’s Q1 2024 Revenues Affected by COVID-19 Project Exclusion
China’s leading Contract Research Organization (CRO), WuXi AppTec (HKG: 2359, SHA: 603259), has announced its...
EOC Pharma’s Entinostat Secures Chinese Approval for Breast Cancer Treatment
US-China biotech firm EOC Pharma has received market approval from China’s National Medical Products Administration...
Bristol-Myers Squibb Prepares Contingency Plans in Response to the Biosecure Act
Bristol-Myers Squibb (BMS; NYSE: BMY), a leading U.S. pharmaceutical company, is reportedly drafting ‘contingency plans’...
Daiichi Sankyo Reports 25.3% Revenue Growth in FY2023, Boosted by Enhertu and Lixiana Sales
Japanese pharmaceutical company Daiichi Sankyo has reported a remarkable fiscal year 2023, with revenues increasing...
China’s National Drug Alliance Procurement Office Announces Insulin VBP Re-Tender Results
The National Drug Alliance Procurement Office in China has published the winning results of the...
RemeGen’s Q1 2024 Revenues Surge 96.41% YOY, R&D Spending Outpaces Income
China-based pharmaceutical company RemeGen (HKG: 9995) has reported its financial results for the first quarter...
Astellas Pharma Inc. Reports Revenue Growth in FY2023, Driven by Xtandi and Padcev Sales
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced its financial results for the year ended...